Answers are grounded in this paper and cite their sources.
Cytokines of the interleukin (IL)-1 family are key mediators of cutaneous innate immunity. While the activation and function of IL-1β and IL-18 during immune responses are well characterized, the immunological properties of IL-33 are less well understood. The functions of exogenous IL-33, the therapeutic application of recombinant IL-33, and the interaction between IL-33 and its receptor ST2 are largely elucidated. In contrast, the function of endogenous IL-33 (eIL-33) is yet unknown. By investigating the immune responses in 2 different Th17-mediated experimental disease models, autoimmune encephalomyelitis and imiquimod-induced psoriasis, we found that eIL-33 dampened the Th17 immune response in vivo. Mechanistically, the absence of eIL-33 induced a stronger proinflammatory phenotype in dendritic cells (DCs), resulting in a stronger Th17 response in vivo and in vitro. Furthermore, eIL-33 influenced the expression of costimulatory molecules on antigen-presenting cells. On the molecular level, eIL-33 regulated genes like Icosl, Il12b, and Ccl17, which are associated with inflammatory autoimmune diseases. These findings demonstrate that the pleiotropic cytokine IL-33 influences, depending on its exogenous secreted or endogenous intracellular form, several signaling pathways. With these data we could unravel the mechanism of how intracellular IL-33 influences the phenotype of DCs to attenuate the differentiation of pathogenic Th17 cells.
No takes yet. Share an insight, caveat, or question.
Brück et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: